New combo therapy shows promise for lymphoma in seniors
NCT ID NCT00690560
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 19 times
Summary
This study tested a combination of chemotherapy (CHOP), a targeted antibody (rituximab), and a radioactive antibody (Y90 ibritumomab tiuxetan) in 30 adults aged 65-80 with newly diagnosed large B-cell lymphoma. The goal was to see if this approach could improve event-free survival. Participants received the treatment in two phases: initial chemo-immunotherapy followed by a consolidation step with the radioactive antibody.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France
Conditions
Explore the condition pages connected to this study.